assay. To estimate the analytical performance of Ventana ALK and OFA in an orthogonal analysis; a total of 50 samples (22 Ventana ALK and OFA negatives, 9 Ventana ALK+, 7 OFA+, and 12 Ventana ALK and OFA positives) were analyzed using a qPCR based EML4-ALK fusion gene detection kit (AmoyDx) as benchmark. Results: The frequencies of ALK fusions detected were 3,76% and 3,69% by Ventana ALK and OFA respectively, with 57,1% of samples giving discordant results between Ventana ALK and OFA techniques. The orthogonal analysis revealed that both, Ventana ALK and OFA, have a sensitivity of 75% [CI95%:51 -91]. However, OFA presents higher specificity than Ventana ALK (96% vs. 88%). This difference has a post hoc statistical power of 97%. While Ventana ALK test can detect only the aberrant ALK accumulation, by using NGS it was possible to establish that the most common ALK gene fusion was between exon 20 of ALK and 6 of EML4. Conclusion: Considering this analysis a preliminary assessment, when OFA and Ventana ALK are compared using "real world" lung adenocarcinoma samples, OFA presents an advantage against Ventana ALK test in specificity. Also, NGS can detect multiple mutations at the same time using a small amount of sample. The use of this technique unlocks the possibility to identify patients that can be treated using targeted therapies. We also reviewed statistics of the Ministries of Health and/or National Institutes of Cancer, but we exclude them because their heterogenity. We consider age-standarized rates per 100000 (ASR) to make fairer comparisons between groups with different age distributions. Analysis was performed by tumor site (excluding non-melanoma skin) and by country, and sex. Results: Cancer mortality for the region is 94.9 for both sexes and lung cancer mortality is the third cause (12.0) behind prostate and breast cancer (16.6, 13.0). For men, cancer mortality rate is 108.4 and lung cancer is the first cause (16.7) followed closely by prostate cancer (16.6). For women cancer mortality is 84.7 and lung cancer is the third cause (8.1), mama and cervix are the first (13.0, 8.7). The lung cancer mortality in males by country showed that Uruguay, Cuba and Argentina present the higher mortality (47.1, 39.6, 30.9). It was the first cause cancer mortality in those countries and in Brazil and Paraguay also, and the second in Mexico, Dominican Republic and Venezuela. In women, lung cancer mortality is higher in Cuba, Venezuela, Argentina and Brazil (21.6, 10.5, 10.0, 9.5), but it is the principal cause of cancer mortality only in Cuba and the second one in Brazil. The analysis is limited by registry quality. Conclusion: Latin America lung cancer mortality is heterogenous between countries. In men is the first cause in only 25% of the countries analyzed, the second in 15 %. In women it is only first in one country and second in another. Better understanding the region could adapt screening and early detection plans and may improve patients access to diagnosis and treatment in a precise way and opportunity.
assay. To estimate the analytical performance of Ventana ALK and OFA in an orthogonal analysis; a total of 50 samples (22 Ventana ALK and OFA negatives, 9 Ventana ALK+, 7 OFA+, and 12 Ventana ALK and OFA positives) were analyzed using a qPCR based EML4-ALK fusion gene detection kit (AmoyDx) as benchmark. Results: The frequencies of ALK fusions detected were 3,76% and 3,69% by Ventana ALK and OFA respectively, with 57,1% of samples giving discordant results between Ventana ALK and OFA techniques. The orthogonal analysis revealed that both, Ventana ALK and OFA, have a sensitivity of 75% [CI95%: 51 -91] . However, OFA presents higher specificity than Ventana ALK (96% vs. 88%). This difference has a post hoc statistical power of 97%. While Ventana ALK test can detect only the aberrant ALK accumulation, by using NGS it was possible to establish that the most common ALK gene fusion was between exon 20 of ALK and 6 of EML4. Conclusion: Considering this analysis a preliminary assessment, when OFA and Ventana ALK are compared using "real world" lung adenocarcinoma samples, OFA presents an advantage against Ventana ALK test in specificity. Also, NGS can detect multiple mutations at the same time using a small amount of sample. The use of this technique unlocks the possibility to identify patients that can be treated using targeted therapies. (68.4y vs. 66.1y; p¼0.295) and mean primary tumor size were similar (0.215) between Good and Poor groups. Histology (i.e. adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, etc.) were similar between Good and Poor groups (p¼0.209). Differentiation grade, N status, and M status differed between Good and Poor groups, with the Poor group having proportionately more poorly-differentiated (G3) tumors (p¼0.019), mediastinal N2 and N3 involvement (p<0.01), and more M1 status (p<0.01). Treatment differed between Good and Poor groups, with the Good group more often had surgery or radiation alone, while the Poor group more often had systemic therapy (p¼0.001). In Kaplan-Meier analysis, the Good group had 1-yr overall survival (OS) of 87.6% compared to a 1-yr OS of 63.3% for the Poor group (p<0.01). Conclusion: Using a commercially-available peripheral blood liquid biopsy kit, mutation-negative NSCLC patients were identified by ctDNA analysis and as Good or Poor status by proteomic analysis. While age, tumor size, or T status did not correlate with Good versus Poor status, the Poor group had more poorly-differentiated tumors, more mediastinal N2 and N3 involvement, and more distant metastases, required systemic therapy more often, and had worse 1-yr OS than proteomicGood patients. Keywords: outcomes, nonesmall cell lung cancer, Liquid Biopsy, histopathology
